KalVista Pharmaceuticals (NASDAQ:KALV) Upgraded to Buy at Wall Street Zen

Key Points

• Wall Street Zen upgraded KalVista from "hold" to "buy," joining other analysts (seven Buy vs. one Sell) and supporting a consensus rating of "Moderate Buy" with a consensus target price of $32.60.
• EKTERLY commercial launch generated $49.1M in revenue during an eight‑month transition, a material proof point as shares trade around $19.33 (52‑week high $19.95) with a market cap near $990M.
• Insiders have been selling recently—33,378 shares (~$522K) sold in the last 90 days—leaving insiders with about 4.3% ownership, which may temper interpretation of the analyst bullishness.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research report issued on Saturday.

A number of other equities research analysts also recently issued reports on KALV. HC Wainwright increased their price target on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the stock a "buy" rating in a report on Friday, January 9th. Citizens Jmp reduced their price objective on shares of KalVista Pharmaceuticals from $29.00 to $28.00 and set a "market outperform" rating for the company in a research note on Thursday. TD Cowen reaffirmed a "buy" rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Stifel Nicolaus raised their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a "buy" rating in a report on Thursday. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, KalVista Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $32.60.

KalVista Pharmaceuticals Stock Up 2.0%

Shares of NASDAQ KALV opened at $19.33 on Friday. KalVista Pharmaceuticals has a 52 week low of $9.23 and a 52 week high of $19.95. The business has a 50-day simple moving average of $16.04 and a two-hundred day simple moving average of $14.46. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. The company has a market cap of $990.08 million, a P/E ratio of -4.89 and a beta of -0.35.

Insiders Place Their Bets

In other news, insider Paul K. Audhya sold 5,354 shares of the business's stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $83,361.78. Following the completion of the transaction, the insider owned 138,983 shares of the company's stock, valued at approximately $2,163,965.31. The trade was a 3.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Brian Piekos sold 1,767 shares of the company's stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $27,512.19. Following the completion of the transaction, the chief financial officer owned 13,762 shares in the company, valued at approximately $214,274.34. This trade represents a 11.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 33,378 shares of company stock worth $522,290. Insiders own 4.30% of the company's stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC bought a new stake in shares of KalVista Pharmaceuticals during the 1st quarter worth $646,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in KalVista Pharmaceuticals by 13.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,325 shares of the specialty pharmaceutical company's stock valued at $281,000 after acquiring an additional 2,939 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in KalVista Pharmaceuticals by 3.7% in the first quarter. Goldman Sachs Group Inc. now owns 339,936 shares of the specialty pharmaceutical company's stock valued at $3,923,000 after acquiring an additional 12,263 shares during the last quarter. Geode Capital Management LLC raised its position in KalVista Pharmaceuticals by 2.8% during the second quarter. Geode Capital Management LLC now owns 941,212 shares of the specialty pharmaceutical company's stock valued at $10,642,000 after purchasing an additional 25,971 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey raised its position in KalVista Pharmaceuticals by 26.8% during the second quarter. Police & Firemen s Retirement System of New Jersey now owns 9,756 shares of the specialty pharmaceutical company's stock valued at $110,000 after purchasing an additional 2,061 shares in the last quarter.

Trending Headlines about KalVista Pharmaceuticals

Here are the key news stories impacting KalVista Pharmaceuticals this week:

• Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
• Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a "buy" rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
• Positive Sentiment: Needham & Company increased its target to $36 and kept a "buy" rating, reinforcing analyst conviction from multiple firms. Needham target raise
• Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
• Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
• Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
• Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a "market outperform"), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.